Luke Evnin, Ph.D.Dr. Luke Evnin joined MPM in 1998 to launch MPM's first venture fund and established the San Francisco office for the firm in 1999. Dr. Evnin was at Accel Partners for over seven years including four as a General Partner. He was involved in biopharmaceutical, medical device and healthcare service companies for Accel's funds III, IV and V. Dr. Evnin earned his Ph.D. in the Department of Biochemistry at the University of California-San Francisco, and he received his A.B. in Molecular Biology magna cum laude from Princeton University . Dr. Evnin is currently a Director of Enteromedics (NASDAQ:ETRM), Metabasis Therapeutics (NASDAQ:MBRX), Oxagen, Peptimmune, Restore Medical (NASDAQ:REST) and Pacira (SkyePharma). He was previously a Director at Idun Pharmaceuticals, Oscient (NASDAQ:OSCI) Sonic Innovations (NASDAQ:SNCI), Epic Therapeutics, EPIX Medical (NASDAQ:EPIX), Signal Pharmaceuticals and several other private companies. |
|
